Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

Published:2018-06-29 Issue:50 Volume:9 Page:29525-29531
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Ichihara Eiki¹,Hotta Katsuyuki²,Kubo Toshio³,Higashionna Tsukasa⁴,Ninomiya Kiichiro¹,Ohashi Kadoaki⁵,Tabata Masahiro³,Maeda Yoshinobu⁵,Kiura Katsuyuki¹

Affiliation:

1. Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan

2. Center for Innovative Clinical Oncology, Okayama University Hospital, Okayama, Japan

3. Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan

4. Department of Clinical Pharmaceutics, Okayama University Hospital, Okayama, Japan

5. Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer;Frontiers in Oncology;2024-08-26

2. Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?;Cancer Research and Treatment;2023-10-15

3. Real‐world data on efficacy and safety of osimertinib in non‐small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy;Asia-Pacific Journal of Clinical Oncology;2023-02-09

4. First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study;Journal of Cancer Research and Clinical Oncology;2022-04-06

5. Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma;Cancer Management and Research;2022-03